The biotech stock is feeling the heat from an indictment of a former consultant.
Battered by controversy, this company will need to show real results to prosper.
Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.
The company has chosen an offbeat way to keep its investors sweet.
Investors cheered the arrival of a trio of new board members.
Playing the blame game does not make for an effective turnaround strategy.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such...
Investors are worried about a leaked report related to alleged data manipulation for Cassava's Alzheimer's disease treatment candidate.
Cassava bounced back from hitting a 52-week low to start the week.
The company announced phase 3 trial results for its lead Alzheimer's therapy.